Reference number : 236-2012-2013-Q3-00030, amendment number : , agreement type : G, recipient legal name : DEB, Saswata, recipient country : CA, recipient province : ON, recipient city : Toronto, recipient postal code : M5S 1A1, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 150000.0, agreement start date : 2013-01-01, agreement end date : 2015-12-31, description english : SUrgical and Pharmacological novel intERventions to Improve Overall Results of Saphenous Vein Graft patency in coronary artery bypass grafting surgery. The "SUPERIOR SVG" Study: An International Multi-centred Randomized Controlled Clinical Trial, description french : SUrgical and Pharmacological novel intERventions to Improve Overall Results of Saphenous Vein Graft patency in coronary artery bypass grafting surgery. The "SUPERIOR SVG" Study: An International Multi-centred Randomized Controlled Clinical Trial, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2012-13 to 2015-16)

Start date may be subject to change.  Funding for awards must commence within 12 months of the date of offer., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2012-13 à 2015-16)

La date de début peut être sujet au changement.  Le financement des bourses doit commencer dans les 12 mois suivant la date à laquelle elles ont été offertes., owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada